• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组蛋白去甲基化酶 Jumonji 结构域蛋白 6(JMJD6)在 IDH 野生型胶质母细胞瘤患者中高表达但无预后意义。

The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients.

机构信息

From the Department of Pathology, Odense University Hospital, Odense, Denmark.

Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

出版信息

J Neuropathol Exp Neurol. 2022 Jan 21;81(1):54-60. doi: 10.1093/jnen/nlab124.

DOI:10.1093/jnen/nlab124
PMID:34875075
Abstract

Patients with IDH-wildtype glioblastoma (GBM) generally have a poor prognosis. However, there is an increasing need of novel robust biomarkers in the daily clinico-pathological setting to identify and support treatment in patients who become long-time survivors. Jumonji domain-containing protein 6 (JMJD6) is involved in epigenetic regulation of demethylation of histones and has been associated with GBM aggressiveness. We investigated the expression and prognostic potential of JMJD6 tumor fraction score in 184 IDH-wildtype GBMs. Whole-slides were double-stained with an antibody against JMJD6 and an exclusion-cocktail consisting of 4 antibodies (CD31, SMA, CD45, and Iba-1), enabling evaluation of tumor cells only. Stainings were quantified with a combined software- and scoring-based approach. For comparison, IDH-mutated WHO grade II, III and IV astrocytic gliomas were also stained, and the JMJD6 tumor fraction score increased with increasing WHO grade, although not significantly. In multivariate analysis including age, gender, performance status and post-surgical treatment high JMJD6 tumor fraction score was associated with longer overall survival in IDH-wildtype GBMs (p = 0.03), but the effect disappeared when MGMT promoter status was included (p = 0.34). We conclude that JMJD6 is highly expressed in IDH-wildtype GBM but it has no independent prognostic value.

摘要

IDH 野生型胶质母细胞瘤(GBM)患者的预后通常较差。然而,在日常临床病理环境中,需要新型强大的生物标志物来识别和支持那些成为长期幸存者的患者的治疗。含有 Jumonji 结构域的蛋白 6(JMJD6)参与组蛋白去甲基化的表观遗传调控,与 GBM 的侵袭性有关。我们研究了 184 例 IDH 野生型 GBM 中 JMJD6 肿瘤分数评分的表达和预后潜力。使用针对 JMJD6 的抗体和包含 4 种抗体(CD31、SMA、CD45 和 Iba-1)的排除鸡尾酒对全切片进行双重染色,仅评估肿瘤细胞。使用软件和评分相结合的方法对染色进行定量。为了比较,还对 IDH 突变的 WHO 二级、三级和四级星形细胞瘤进行了染色,JMJD6 肿瘤分数评分随着 WHO 分级的增加而增加,尽管没有显著差异。在包括年龄、性别、表现状态和手术后治疗的多变量分析中,高 JMJD6 肿瘤分数评分与 IDH 野生型 GBM 的总生存期延长相关(p=0.03),但当包括 MGMT 启动子状态时,这种相关性消失(p=0.34)。我们的结论是,JMJD6 在 IDH 野生型 GBM 中高度表达,但它没有独立的预后价值。

相似文献

1
The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients.组蛋白去甲基化酶 Jumonji 结构域蛋白 6(JMJD6)在 IDH 野生型胶质母细胞瘤患者中高表达但无预后意义。
J Neuropathol Exp Neurol. 2022 Jan 21;81(1):54-60. doi: 10.1093/jnen/nlab124.
2
Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.成人脑胶质瘤的靶向下一代测序用于回顾性预后评估和前瞻性诊断。
Neuropathol Appl Neurobiol. 2021 Feb;47(1):108-126. doi: 10.1111/nan.12645. Epub 2020 Aug 17.
3
Predictive value of MGMT promoter methylation on the survival of TMZ treated -mutant glioblastoma.MGMT 启动子甲基化对替莫唑胺治疗的突变型胶质母细胞瘤患者生存的预测价值。
Cancer Biol Med. 2021 Feb 15;18(1):272-282. doi: 10.20892/j.issn.2095-3941.2020.0179.
4
Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.端粒酶逆转录酶(TERT)启动子突变对弥漫性胶质瘤中异柠檬酸脱氢酶(IDH)突变和O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子甲基化的临床意义
Pathol Res Pract. 2018 Jun;214(6):881-888. doi: 10.1016/j.prp.2018.04.002. Epub 2018 Apr 5.
5
The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.神经病理学在新诊断的胶质母细胞瘤管理中的作用:系统评价和基于证据的临床实践指南。
J Neurooncol. 2020 Nov;150(2):143-164. doi: 10.1007/s11060-020-03616-3. Epub 2020 Nov 19.
6
Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.IDH 野生型胶质母细胞瘤队列中长生存的分子相关性。
J Neuropathol Exp Neurol. 2020 Aug 1;79(8):843-854. doi: 10.1093/jnen/nlaa059.
7
Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.TERT、EGFR和IDH状态的联合分析定义了不同预后的胶质母细胞瘤类别。
Neurology. 2014 Sep 23;83(13):1200-6. doi: 10.1212/WNL.0000000000000814. Epub 2014 Aug 22.
8
Expression of Olig2, Nestin, NogoA and AQP4 have no impact on overall survival in IDH-wildtype glioblastoma.Olig2、Nestin、NogoA 和 AQP4 的表达与 IDH 野生型胶质母细胞瘤的总生存期无关。
PLoS One. 2020 Mar 11;15(3):e0229274. doi: 10.1371/journal.pone.0229274. eCollection 2020.
9
O-methylguanine-DNA methyltransferase promoter methylation and isocitrate dehydrogenase mutation as prognostic factors in a cohort of Saudi patients with glioblastoma.O-甲基鸟嘌呤-DNA甲基转移酶启动子甲基化和异柠檬酸脱氢酶突变作为沙特胶质母细胞瘤患者队列中的预后因素。
Ann Saudi Med. 2019 Nov-Dec;39(6):410-416. doi: 10.5144/0256-4947.2019.410. Epub 2019 Dec 5.
10
PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.PROX1是一种用于高级别星形细胞瘤的新型通路特异性预后生物标志物;来自按年龄和异柠檬酸脱氢酶(IDH)突变状态分层的独立胶质母细胞瘤队列的结果。
Oncotarget. 2016 Nov 8;7(45):72431-72442. doi: 10.18632/oncotarget.11957.

引用本文的文献

1
JMJD6 K375 acetylation restrains lung cancer progression by enhancing METTL14/m6A/SLC3A2 axis mediated cell ferroptosis.JMJD6 K375乙酰化通过增强METTL14/m6A/SLC3A2轴介导的细胞铁死亡来抑制肺癌进展。
J Transl Med. 2025 Feb 26;23(1):233. doi: 10.1186/s12967-025-06241-8.